Investing.com - Halozyme (NASDAQ: HALO) reported fourth quarter EPS of $0.48, $0.18 better than the analyst estimate of $0.30. Revenue for the quarter came in at $181M versus the consensus estimate of $192.05M.
Guidance
Halozyme sees FY 2023 revenue of $815.00M-$845.00M versus the analyst consensus of $868.12M.
Halozyme's stock price closed at $49.66. It is down -8.63% in the last 3 months and up 51.45% in the last 12 months.
Halozyme saw 1 positive EPS revisions and 4 negative EPS revisions in the last 90 days. See Halozyme's stock price’s past reactions to earnings here.
According to InvestingPro, Halozyme's Financial Health score is "great performance".
Check out Halozyme's recent earnings performance, and Halozyme's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar